| CIS | carcinoma in situ; catheter-induced spasm; central inhibitory state; Chemical Information Service; c... |
|---|---|
| CM | California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ... |
| CPS | carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ... |
| DCP | dicalcium phosphate; Diploma in Clinical Pathology; Diploma in Clinical Psychology; District Communi... |
| C/F | Clinical Finding |
| statistical genetics | The study of the applications of principles of statistics to problems in genetics. (05 Mar 2000) |
|---|---|
| q in population genetics | The frequency of the less common of two different alternative (allelic) versions of a gene. (the frequency of the more common allele is p). (12 Dec 1998) |
| quantitative genetics | The formal study of measurable genetic traits, traditionally but not necessarily confined to galtonian genetics. (05 Mar 2000) |
| terminator regions (genetics) | DNA sequences which signal the termination of transcription. (12 Dec 1998) |
| trans-activation (genetics) | Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.) (12 Dec 1998) |
| translocation (genetics) | A type of aberration characterised by fragmentation of a chromosome and transfer of the broken-off portion to another chromosome, often of a different pair. (12 Dec 1998) |
| transplantation genetics | Genetics as applied to the transplanting of tissues from one animal to another. (05 Mar 2000) |
| epidemiological genetics | The study of genetics as a phenomenon of defined populations by the criteria, methods, and objectives of epidemiology rather than of population genetics. (05 Mar 2000) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |